AD 2239

structure given in first source

Also Known As:

1-(2,3-dimethyl-4-methoxyphenyl)-2-methyl-3-(1-pyrrolidinyl)-1-propanone HCl; 1-propanone, 1-(4-methoxy-2,3-dimethylphenyl)-2-methyl-3-(1-pyrrolidinyl)-, hydrochloride; AD-2239

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - AD 2239: 1

Related Diseases

1.	Spasm (Spasms) 05/01/1985 - "The results strongly suggest that AD-2239 may have advantages over the existing centrally acting muscle relaxants in the treatment of human clinical spasticity and muscle spasm syndromes."
2.	Decerebrate State 05/01/1985 - "AD-2239 produced a dose-related reduction of anemic decerebrate rigidity (alpha-rigidity) in rats. "

Related Drugs and Biologics

1.	Central Muscle Relaxants